These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28625126)

  • 1. Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
    Chen CC; Hsu CC; Huang CE; Chen YY; Lung J; Ho HY; Li CP; Lee JD
    Curr Neurovasc Res; 2017; 14(3):222-231. PubMed ID: 28625126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
    Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
    Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
    Zulkeflee RH; Zulkafli Z; Johan MF; Husin A; Islam MA; Hassan R
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
    Dong L; Shen XL; Wei W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in
    Wang Y; Ran F; Lin J; Zhang J; Ma D
    Technol Cancer Res Treat; 2023; 22():15330338231154092. PubMed ID: 36744404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].
    Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090
    [No Abstract]   [Full Text] [Related]  

  • 9. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
    Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
    PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
    Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
    Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation analysis between JAK2, MPL, and CALR mutations in patients with myeloproliferative neoplasms of Chinese Uygur and Han nationality and their clinical characteristics.
    Lang T; Nie Y; Wang Z; Huang Q; An L; Wang Y; Wufuer G; Maimaiti A; Fu L; Li Y; Zhang X; Aisimutula A; Wang X; Zhu L; Liu H; Mao M
    J Int Med Res; 2018 Nov; 46(11):4650-4659. PubMed ID: 30084272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
    Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
    Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
    Barbui T; Falanga A
    Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
    Chen CC; Gau JP; Chou HJ; You JY; Huang CE; Chen YY; Lung J; Chou YS; Leu YW; Lu CH; Lee KD; Tsai YH
    Ann Hematol; 2014 Dec; 93(12):2029-36. PubMed ID: 25015052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of genetic data to clinical practice of MPN].
    Edahiro Y
    Rinsho Ketsueki; 2015 Aug; 56(8):949-55. PubMed ID: 26345552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients.
    Shires KL; Rust AJ; Harryparsad R; Coburn JA; Gopie RE
    Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):291-302. PubMed ID: 37023224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.